Clinical Trials Logo

Breakthrough Pain clinical trials

View clinical trials related to Breakthrough Pain.

Filter by:

NCT ID: NCT06308328 Recruiting - Clinical trials for Swallowing-induced Breakthrough Pain

A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis

Start date: April 1, 2024
Phase:
Study type: Observational

The performance of the predictive models for the occurrence and severity of oropharyngeal mucositis established using either oral cavity contouring method or mucosa surface contouring method was unsatisfactory in nasopharyngeal carcinoma (NPC). Whereas the predictive model of a mucosal contouring method based on swallowing-induced breakthrough pain exhibited better overall performance in locally advanced NPC. Therefore, the investigators aimed to conduct a prospective, multicenter, real-world observational study to further assess the predictive efficacy of this mucosal delineation method for radiation-induced oropharyngeal mucositis in NPC.

NCT ID: NCT06287788 Recruiting - Clinical trials for Swallowing-induced Breakthrough Pain

A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis

Start date: March 1, 2024
Phase:
Study type: Observational

The performance of the predictive models for severe oropharyngeal mucositis established using current oral mucosal contouring method was unsatisfactory in nasopharyngeal carcinoma (NPC). Whereas the predictive model of a mucosal contouring method based on swallowing-induced breakthrough pain exhibited better overall performance. The aim of this prospective, multicenter, observational study was to further explore the predictive efficacy of this mucosal delineation method for radiation-induced oropharyngeal mucositis in NPC.

NCT ID: NCT06017895 Recruiting - Clinical trials for Swallowing-induced Pain

Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore the effectiveness and adverse reactions of doxepin solution spray for alleviation of stubborn breakthrough pain induced by swallowing in patients receiving radiotherapy for nasopharyngeal carcinoma.

NCT ID: NCT05531422 Not yet recruiting - Breakthrough Pain Clinical Trials

Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP

Start date: September 20, 2022
Phase: Phase 2
Study type: Interventional

Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. This is a phase IIa dose-response and safety study of inhaled fentanyl aerosol (25µg/dose) in Chinese patients with breakthrough cancer pain.

NCT ID: NCT05200806 Recruiting - Analgesia Clinical Trials

A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy

Start date: February 7, 2022
Phase: Phase 4
Study type: Interventional

With this pilot investigation, the investigators aim to challenge the reliance on opiate analgesia following colon and rectal surgery. Narcotic misuse and abuse is a pressing public health concern, and reduction in prescription rates could help to mitigate this issue. The goal of this pilot study is to establish feasibility of sufficient post-operative pain control after colectomy using non-narcotic analgesics. The investigators hypothesize that patients will be able to manage their post-operative pain without narcotic intervention, while minimizing side effects and complications. This initial pilot study will provide proof-of-concept for a larger, randomized investigation on non-narcotic analgesia after colectomy.

NCT ID: NCT05053308 Withdrawn - Cancer Pain Clinical Trials

Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

Proportional dose of sublingual fentanyl tablet (Narco®) based on daily opioid requirement versus intravenous PCA for breakthrough cancer pain: A prospective, randomized, open-label, noninferiority trial.

NCT ID: NCT05037539 Completed - Pain, Breakthrough Clinical Trials

Efficacy of Injectable Fentanyl in Sublingual Route Versus Oral Morphine Syrup for Breakthrough Pain

Start date: June 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Randomized control trial that to comparison the efficacy of injectable fentanyl in sublingual route versus oral morphine syrup for breakthrough pain in gynecologic cancer patients with chronic cancer pain Primary outcome : to measure pain score after drug is given

NCT ID: NCT04011150 Recruiting - Labor Pain Clinical Trials

Development of Variable Volume Automated Mandatory Boluses for Patient-controlled Epidural Analgesia During Labour

VVAMB
Start date: August 11, 2020
Phase: Phase 3
Study type: Interventional

A novel epidural delivery regimen was developed: Variable volume automated mandatory bolus (AMB) (VVAMB) will advance individualisation of labour epidural analgesia, by which a larger volume of bolus may contribute to better spread of the local anaesthetics within brief period and thereby reduces the chances of motor blockade that could reduce instrumental deliveries.

NCT ID: NCT03809455 Withdrawn - Breakthrough Pain Clinical Trials

Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients

FARADI
Start date: February 1, 2020
Phase: Phase 2
Study type: Interventional

A phase II, prospective, multicentre, single-blinded, randomised study (when fentanyl citrate is used outside of its marketing authorisation) Patients will be enrolled in an observational cohort when the fentanyl citrate is used according to its marketing authorisation.

NCT ID: NCT03669263 Completed - Clinical trials for Breakthrough Cancer Pain

A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan

Start date: November 25, 2014
Phase: N/A
Study type: Interventional

Primary Objective: To determine the feasible dose range of Painkyl® required for Taiwanese population. Secondary Objectives: To evaluate the efficacy of Painkyl® by calculating squared mean of pain intensity difference at 30 minutes after taking Painkyl® (SPID30, an 11-point scale). To evaluate subjects' satisfaction by conducting global evaluation of medication performance (a 5-point categorical scale). To identify percentage of episodes requiring rescue medication during maintenance treatment period. To evaluate the safety data of Painkyl® for breakthrough pain.